Skip to content
SeqOne Genomics
  • Diagnostics
  • Biopharma
  • Platform
    • Overview
    • Therapeutic areas
    • Quality
    • Features
    • Bioinformatic apps
    • Technical specifications
  • About us
    • Who we are
    • Science
    • Press
  • News
  • Contact & demo
  • Login
SeqOne Genomics
SeqOne Genomics
  • Diagnostics
  • Biopharma
  • Platform
    • Overview
    • Therapeutic areas
    • Quality
    • Features
    • Bioinformatic apps
    • Technical specifications
  • About us
    • Who we are
    • Science
    • Press
  • News
  • Contact & demo
  • Login

Archives: Hot news

New HRD genetic test

Michael Blum is SeqOne’s new Head of Research and Development

SeqOne Genomics announces Portuguese distribution partnership

Unicancer and SeqOne collaborate on genomic knowledge sharing

SeqOne closes €20M series A to accelerate deployment of its genomic medicine platform

Auragen chooses SeqOne for genomic interpretation

Recent Posts

  • SeqOne at ESHG 2023: A.I. for Diagnostics
  • SeqOne’s new clinically validated HRD test reduces the number of inconclusive results to improve the prescription of targeted treatments for ovarian cancer patients
  • SeqOne Genomics and the French Thrombotic MicroAngiopathies National reference center (CNR-MAT) pioneer the use of Oxford Nanopore sequencing technology to improve patient outcomes in kidney disease while reducing turnaround times
  • Michael Blum joins SeqOne Genomics to head the company’s Research and Development
  • SeqOne Genomics announces Portuguese distribution partnership

Recent Comments

  • AffiliateLabz on EUROFINS BIOMNIS AND SEQONE PARTNER TO IMPROVE CLINICAL ACCESS TO WHOLE EXOME TESTING
  • ExoRank.com on EUROFINS BIOMNIS AND SEQONE PARTNER TO IMPROVE CLINICAL ACCESS TO WHOLE EXOME TESTING

Stay in the loop

Get notified of SeqOne new annoucements.

loader

Your e-mail address will be used to send you our newsletter. Learn more about our privacy policy.

Next generation genomics for next generation healthcare.

© SeqOne 2023 – All rights reserved.

Menu

  • Home
  • Platform
  • Science
  • About us
  • News
  • Contact & demo
  • Platform login
  • Privacy & cookie policy
  • Cookie settings

Solutions for

  • Diagnostics
  • Biopharma

Applications

  • Rare and hereditary diseases
  • Hereditary cancer predisposition
  • Somatic cancers

Contact us

+33 (0)9 54 40 42 84
contact@seqone.com

SeqOne S.A.S.
22 rue Durand
34000 Montpellier,
France

  • Diagnostics
  • Biopharma
  • Platform
    • Overview
    • Therapeutic areas
    • Quality
    • Features
    • Bioinformatic apps
    • Technical specifications
  • About us
    • Who we are
    • Science
    • Press
  • News
  • Contact & demo
  • Login